Skip to Main Content

++

OVERVIEW

++

AMIODARONE

++

Amiodarone is designated as a class III antiarrhythmic drug based on the Vaughan Williams classification. Consistent with other class III antiarrhythmic drugs, amiodarone blocks potassium channels to delay phase 3 repolarization.1 However, amiodarone possesses electrophysiological (EP) effects similar to all four classes of antiarrhythmic drugs by (1) blocking sodium channels (class I effect)2, (2) potent nonselective, noncompetitive β-adrenergic receptor blockade (class II effect)3, and (3) antagonizing calcium channel activity (class IV effect). As a result, amiodarone prolongs action potential duration (APD), resulting in prolongation of the effective refractory period.1

++

Amiodarone is indicated for the treatment of life-threatening, recurrent, refractory ventricular arrhythmias,4 including recurrent ventricular fibrillation (VF)5 and recurrent hemodynamically unstable ventricular tachycardia (VT).6 In addition to these indications, amiodarone is commonly used for treatment of atrial fibrillation (AF) particularly in patients with heart failure.7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24 According to the 2011 consensus guidelines of the American Heart Association (AHA) and the American College of Cardiology (ACC) for the management of atrial fibrillation,25 amiodarone can also be used for cardioversion of recent-onset AF.26 Amiodarone is not only beneficial in terminating AF, but it can be effective at maintaining normal sinus rhythm (NSR) and preventing AF recurrence.27, 28, 29, 30, 31, 32, 33, 34, 35, 36, and 37 The Canadian trial of AF (CTAF) reported that amiodarone reduced the incidence of recurrent AF compared to other antiarrhythmic drugs (35% vs. 63%, respectively).29 Additional studies have demonstrated that amiodarone is effective at preventing AF following cardiovascular and cardiothoracic surgeries.29,31

++
Dosing
++

Amiodarone dosing varies depending on the clinical indication. Table 1-1 summarizes the dosing recommendations for amiodarone according to AHA recommendations, 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death, and its focused update in 2011 on the management of atrial fibrillation. Amiodarone is commercially available as 100 and 200 mg oral tablets or as 50 mg/mL for IV administration.

++
Table Graphic Jump Location
TABLE 1-1Amiodarone Dosing

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

AccessPharmacy Full Site: One-Year Subscription

Connect to the full suite of AccessPharmacy content and resources including 30+ textbooks such as Pharmacotherapy: A Pathophysiologic Approach and Goodman & Gilman's The Pharmacological Basis of Therapeutics, high-quality videos, images, and animations, interactive board review, drug and herb/supplements databases, and more.

$595 USD
Buy Now

Pay Per View: Timed Access to all of AccessPharmacy

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.